Clinical Trial Update: NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for NT219 in combination with standard of care biologic therapy in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (Phase 1/Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• NT219

Snippet

Sponsor: University of Colorado, Denver | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING